Literature DB >> 34993102

Accuracy of quantitative vessel analysis in endovascular treatment for femoropopliteal lesions.

Shinsuke Mori1, Keisuke Hirano2, Mitsuyoshi Takahara3, Shigemitsu Shirai1, Kenji Makino1, Yohsuke Honda1, Masakazu Tsutsumi1, Norihiro Kobayashi1, Masahiro Yamawaki1, Yoshiaki Ito1.   

Abstract

BACKGROUND: Our aim was to evaluate the accuracy of quantitative vessel analysis (QVA) in measuring the reference vessel diameter (RVD) of femoropopliteal lesions.
METHODS: Between October 2014 and September 2015, 30 consecutive femoropopliteal lesions in 25 patients who underwent endovascular therapy (EVT) under intravascular ultrasound (IVUS) guidance were analyzed. RVDs measured using QVAsheath (calibrated using a 6-Fr sheath in the common femoral artery) and QVAruler (calibrated using a ruler on the angiography table) were compared to those obtained using IVUS as the reference values.
RESULTS: The mean QVAsheath-measured RVD was significantly larger than the mean IVUS-measured RVD (5.34±1.29 vs. 5.07±1.20 mm, P=0.001). In contrast, mean QVAruler-measured RVD was 4.60±1.04 mm, which was significantly smaller than both the mean IVUS- and mean QVAsheath-measured RVD (both P<0.001). Bland-Altman analysis revealed that the 95% limits of agreement versus IVUS ranged from -0.94 to 1.49 mm for QVAsheath and -1.69 to 0.76 mm for QVAruler, respectively. Agreement with tolerance of ±1.00 mm accounted for 88% of QVAsheath and 83% of QVAruler (P=0.60). The difference between QVA- and IVUS-measured RVDs was inversely correlated with the distance from the table (P=0.029 for QVAsheath and P=0.003 for QVAruler).
CONCLUSIONS: The accuracy of both QVAsheath and QVAruler in measuring RVD were similarly suboptimal. Over- and under-estimation of RVD is not rare in QVA. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Quantitative vessel analysis (QVA); accuracy; endovascular therapy (EVT); intravascular ultrasound (IVUS); superficial femoral artery (SFA)

Year:  2022        PMID: 34993102      PMCID: PMC8666758          DOI: 10.21037/qims-20-1097

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  13 in total

1.  Quantitative contrast enhanced magnetic resonance imaging for the evaluation of peripheral arterial disease: a comparative study versus standard digital angiography.

Authors:  Chris Pavlovic; Hideki Futamatsu; Dominick J Angiolillo; Luis A Guzman; Norbert Wilke; Daniel Siragusa; Peter Wludyka; Robert Percy; Martin Northrup; Theodore A Bass; Marco A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2006-07-27       Impact factor: 2.357

2.  Discrepancies in vessel sizing between angiography and intravascular ultrasound varies according to the vessel evaluated.

Authors:  Kensuke Takagi; Joanne Shannon; Sandeep Basavarajaiah; Azeem Latib; Rasha Al-Lamee; Tasuku Hasegawa; Cosmo Godino; Massimo Ferraro; Filippo Figini; Mauro Carlino; Matteo Montorfano; Alaide Chieffo; Antonio Colombo
Journal:  Int J Cardiol       Date:  2013-07-12       Impact factor: 4.164

3.  Clinical impact of self-expandable stent diameter after femoropopliteal stenting.

Authors:  Yoshimitsu Soga; Hiroyoshi Yokoi; Tomoko Urakawa; Masashi Iwabuchi; Masakiyo Nobuyoshi
Journal:  Cardiovasc Interv Ther       Date:  2010-09-03

4.  SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent.

Authors:  Lawrence A Garcia; Kenneth R Rosenfield; Christopher D Metzger; Frank Zidar; Ashish Pershad; Jeffrey J Popma; Margo Zaugg; Michael R Jaff
Journal:  Catheter Cardiovasc Interv       Date:  2017-05-04       Impact factor: 2.692

5.  Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.

Authors:  E Regar; P W Serruys; C Bode; C Holubarsch; J L Guermonprez; W Wijns; A Bartorelli; C Constantini; M Degertekin; K Tanabe; C Disco; E Wuelfert; M C Morice
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

6.  Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results.

Authors:  Stephan H Duda; Benjamin Pusich; Goetz Richter; Peter Landwehr; Vincent L Oliva; Alexander Tielbeek; Benjamin Wiesinger; Jan Bart Hak; Hans Tielemans; Gerhard Ziemer; Ecatarina Cristea; Alexandra Lansky; Jean P Bérégi
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

7.  Evaluation of peripheral atherosclerosis: a comparative analysis of angiography and intravascular ultrasound imaging.

Authors:  Zachary M Arthurs; Paul D Bishop; Lindsay E Feiten; Matthew J Eagleton; Daniel G Clair; Vikram S Kashyap
Journal:  J Vasc Surg       Date:  2010-01-15       Impact factor: 4.268

8.  De novo superficial femoropopliteal artery lesions: peripheral cutting balloon angioplasty and restenosis rates--randomized controlled trial.

Authors:  Jasmin Amighi; Martin Schillinger; Petra Dick; Oliver Schlager; Schila Sabeti; Wolfgang Mlekusch; Markus Haumer; Rainer Mathies; Gerald Heinzle; Antonius Schuster; Christian Loewe; Renate Koppensteiner; Johannes Lammer; Erich Minar; Manfred Cejna
Journal:  Radiology       Date:  2008-02-12       Impact factor: 11.105

9.  Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).

Authors:  Hans Krankenberg; Michael Schlüter; Hermann J Steinkamp; Karlheinz Bürgelin; Dierk Scheinert; Karl-Ludwig Schulte; Erich Minar; Patrick Peeters; Marc Bosiers; Gunnar Tepe; Bernhard Reimers; Felix Mahler; Thilo Tübler; Thomas Zeller
Journal:  Circulation       Date:  2007-06-25       Impact factor: 29.690

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.